|
1
|
American Cancer Society-Facts and Figures:
American Cancer Society Atlanta. GA. 2018.
|
|
2
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Musgrove EA and Sutherland RL: Biological
determinants of endocrine resistance in breast cancer. Nat Rev
Cancer. 9:631–643. 2009.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Johnston SR and Dowsett M: Aromatase
inhibitors for breast cancer: Lessons from the laboratory. Nat Rev
Cancer. 3:821–831. 2003.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
Ma CX, Reinert T, Chmielewska I and Ellis
MJ: Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer.
15:261–275. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Baselga J and Swain SM: Novel anticancer
targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer.
9:463–475. 2009.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
Dinh P, Sotiriou C and Piccart MJ: The
evolution of treatment strategies: Aiming at the target. Breast.
16((Suppl 2)): S10–S16. 2007.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Cleator S, Heller W and Coombes RC:
Triple-negative breast cancer: Therapeutic options. Lancet Oncol.
8:235–244. 2007.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Anders CK, Winer EP, Ford JM, Dent R,
Silver DP, Sledge GW and Carey LA: Poly(ADP-Ribose) polymerase
inhibition: ‘Targeted’ therapy for triple-negative breast cancer.
Clin Cancer Res. 16:4702–4710. 2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ibrahim YH, García-García C, Serra V, He
L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J,
et al: PI3K inhibition impairs BRCA1/2 expression and sensitizes
BRCA-proficient triple-negative breast cancer to PARP inhibition.
Cancer Discov. 2:1036–1047. 2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284.
2005.PubMed/NCBI View
Article : Google Scholar
|
|
12
|
Telang N and Katdare M: Epithelial cell
culture models for the prevention and therapy of clinical breast
cancer (Review). Oncol Lett. 3:744–750. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Telang N, Li G, Katdare M, Sepkovic D,
Bradlow L and Wong G: Inhibitory effects of Chinese nutritional
herbs in isogenic breast carcinoma cells with modulated estrogen
receptor function. Oncol Lett. 12:3949–3957. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Neve RM, Chin K, Fridlyand J, Yeh J,
Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T,
et al: A collection of breast cancer cell lines for the study of
functionally distinct cancer subtypes. Cell. 10:515–527.
2006.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Subik K, Lee JF, Baxter L, Strzepel T,
Costello D, Crowley P, Xing L, Hung MC and Bonfiglio T: Hicks DG
and tangP; Expression patterns of ER, PR, HER-2, CK5/6, Ki-67 and
AR by immune-histochemical analysis in breast cancer cell lines.
Breast Cancer. 4:35–41. 2010.PubMed/NCBI
|
|
16
|
Telang N: Putative cancer-initiating stem
cells in cell culture models for molecular subtypes of clinical
breast cancer. Oncol Lett. 10:3840–3846. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Telang N: Growth inhibitory efficacy of
natural products in a model for triple negative molecular subtype
of clinical breast cancer. Biomed Rep. 7:199–204. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Telang NT, Li G, Sepkovic DW, Bradlow HL
and Wong GY: Anti-proliferative effects of Chinese herb Cornus
officinalis in a cell culture model for estrogen receptor-positive
clinical breast cancer. Mol Med Rep. 5:22–28. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Telang NT, Nair HB and Wong GY: Effect of
Cornus officinalis (CO) on a model for triple negative breast
cancer. Cancer Res. 75((Suppl): SABCS Abstract P3-09-04)2015.
View Article : Google Scholar
|
|
20
|
Telang N, Nair HB and Wong GY: Efficacy of
Disacus asperoides (DA) in a model for triple negative breast
cancer. Cancer Res. 76((Suppl): SABCS Abstract P4-13-04)2016.
View Article : Google Scholar
|
|
21
|
Telang N: Anti-proliferative and
pro-apoptotic effects of rosemary and constituent terpenoids in a
model for the HER-2-enriched molecular subtype of clinical breast
cancer. Oncol Lett. 16:5489–5497. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Jinno H, Steiner MG, Nason-Burchenal K,
Osborne MP and Telang NT: Preventive efficacy of receptor class
selective retinoids on HER-2/neu oncogene expressing preneoplastic
human mammary epithelial cells. Int J Oncol. 21:127–134.
2002.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Subbaramaiah K, Cole PA and Dannenberg AJ:
Retinoids and carnosol suppress cyclooxygenase-2 transcription by
CREB-binding protein/p300-dependent and -independent mechanisms.
Cancer Res. 62:2522–2530. 2002.PubMed/NCBI
|
|
24
|
Seeram NP, Schutzki R, Chandra A and Nair
MG: Characterization, quantification, and bioactivities of
anthocyanins in Cornus species. J Agric Food Chem. 50:2519–2523.
2002.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chang JS, Chiang LC, Hsu FF and Lin CC:
Chemoprevention against hepatocellular carcinoma of Cornus
officinalis in vitro. Am J Chin Med. 32:717–725. 2004.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Sun L, Chen W, Qu L, Wu J and Si J:
Icaritin reverses multidrug resistance of HepG2/ADR human hepatoma
cells via downregulation of MDR1 and P glycoprotein expression. Mol
Med Rep. 8:1883–1887. 2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ma HR, Wang J, Chen YF, Chen H, Wang WS
and Aisa HA: Icariin and icaritin stimulate the proliferation of
SKBr3 cells through the GPER1-mediated modulation of the EGFR-MAPK
signaling pathway. Int J Mol Med. 33:1627–1634. 2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ye L, Jia Y, Ji KE, Sanders AJ, Xue K, Ji
J, Mason MD and Jiang WG: Traditional Chinese medicine in the
prevention and treatment of cancer and cancer metastasis. Oncol
Lett. 10:1240–1250. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Telang NT, Li G, Katdare M, Sepkovic DW,
Bradlow HL and Wong GY: The nutritional herb Epimedium grandiflorum
inhibits the growth in a model for the Luminal A molecular subtype
of breast cancer. Oncol Lett. 13:2477–2482. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Telang NT: Drug resistant breast colon
cancer stem cells: Targeted approach for stem cell therapy. Int J
Mol Med. 42((Suppl 1): S6)2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Takahashi K, Tanabe K, Ohnuki M, Narita M,
Ichisaka T, Tomoda K and Yamanaka S: Induction of pluripotent stem
cells from adult human fibroblasts by defined factors. Cell.
131:861–872. 2007.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Park IH, Zhao R, West JA, Yabuuchi A, Huo
H, Ince TA, Lerou PH, Lensch MW and Daley GQ: Reprogramming of
human somatic cells to pluripotency with defined factors. Nature.
451:141–146. 2008.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yu J, Hu K, Smuga-Otto K, Tian S, Stewart
R, Slukvin II and Thomson JA: Human induced pluripotent stem cells
free of vector and transgene sequences. Science. 324:797–801.
2009.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Nguyen PH, Giraud J, Staedel C,
Chambonnier L, Dubus P, Chevret E, Bœuf H, Gauthereau X, Rousseau
B, Fevre M, et al: All-trans retinoic acid targets gastric cancer
stem cells and inhibits patient-derived gastric carcinoma tumor
growth. Oncogene. 35:5619–5628. 2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Bruna A, Rueda OM, Greenwood W, Batra AS,
Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW,
Tufegdzic-Vidakovic A, et al: A biobank of breast cancer
explantswith preserved intra-tumor heterogeneity to screen
anticancer compounds. Cell. 167(260-274.e22)2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Marangoni E, Laurent C, Coussy F, El-Botty
R, Château-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani
A, Montaudon E, et al: Capecetabine efficacy is correlated with
TYMP and RB1 expression in PDX established from triple negative
breast cancers. Clin Cancer Res. 24:2605–2615. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Sachs N, de Ligt J, Kopper O, Gogola E,
Bounova G, Weeber F, Balgobind AV, Wind K, Gracanin A, Begthel H,
et al: A living biobank of breast cancer organoids captures disease
heterogeneity. Cell. 172(373-386.e10)2018.PubMed/NCBI View Article : Google Scholar
|
